Ductal carcinoma in situ: to treat or not to treat, that is the question.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
14
03
2018
accepted:
22
03
2019
revised:
19
03
2019
pubmed:
10
7
2019
medline:
11
3
2020
entrez:
10
7
2019
Statut:
ppublish
Résumé
Ductal carcinoma in situ (DCIS) now represents 20-25% of all 'breast cancers' consequent upon detection by population-based breast cancer screening programmes. Currently, all DCIS lesions are treated, and treatment comprises either mastectomy or breast-conserving surgery supplemented with radiotherapy. However, most DCIS lesions remain indolent. Difficulty in discerning harmless lesions from potentially invasive ones can lead to overtreatment of this condition in many patients. To counter overtreatment and to transform clinical practice, a global, comprehensive and multidisciplinary collaboration is required. Here we review the incidence of DCIS, the perception of risk for developing invasive breast cancer, the current treatment options and the known molecular aspects of progression. Further research is needed to gain new insights for improved diagnosis and management of DCIS, and this is integrated in the PRECISION (PREvent ductal Carcinoma In Situ Invasive Overtreatment Now) initiative. This international effort will seek to determine which DCISs require treatment and prevent the consequences of overtreatment on the lives of many women affected by DCIS.
Identifiants
pubmed: 31285590
doi: 10.1038/s41416-019-0478-6
pii: 10.1038/s41416-019-0478-6
pmc: PMC6697179
mid: EMS83733
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-292Subventions
Organisme : Cancer Research UK (CRUK)
ID : C38317/A24043
Pays : International
Références
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).
pubmed: 29313949
doi: 10.3322/caac.21442
pmcid: 29313949
American Cancer Society (2017). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf .
Cancer Research UK (2017). http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-in-situ .
Netherlands Comprehensive Cancer Organisation. Online available: www.cijfersoverkanker.nl (Accessed 8 July 2016).
Bane, A. Ductal carcinoma in situ: what the pathologist needs to know and why. Int. J. Breast Cancer 2013, 914053 (2013).
pubmed: 23476791
pmcid: 3580892
doi: 10.1155/2013/914053
Gorringe, K. L. & Fox, S. B. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front Oncol 7, 248 (2017).
Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380, P1778–P1786 (2012).
doi: 10.1016/S0140-6736(12)61611-0
Bleyer, A. & Welch, H. G. Effect of three decades of screening mammography on breast-cancer incidence. N. Engl. J. Med. 367, 1998–2005 (2012).
pubmed: 23171096
doi: 10.1056/NEJMoa1206809
pmcid: 23171096
Bluekens, A. M., Holland, R., Karssemeijer, N., Broeders, M. J. & den Heeten, G. J. Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology 265, 707–714 (2012).
pubmed: 23033499
doi: 10.1148/radiol.12111461
pmcid: 23033499
Ernster, V. L., Ballard-Barbash, R., Barlow, W. E., Zheng, Y., Weaver, D. L., Cutter, G. et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J. Natl. Cancer Inst. 94, 1546–1554 (2002).
pubmed: 12381707
doi: 10.1093/jnci/94.20.1546
Esserman, L. J., Thompson, I. M. Jr. & Reid, B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310, 797–798 (2013).
pubmed: 23896967
doi: 10.1001/jama.2013.108415
Kuerer, H. M., Albarracin, C. T., Yang, W. T., Cardiff, R. D., Brewster, A. M., Symmans, W. F. et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J. Clin. Oncol. 27, 279–288 (2009).
pubmed: 19064970
doi: 10.1200/JCO.2008.18.3103
Siziopikou, K. P. Ductal carcinoma in situ of the breast: current concepts and future directions. Arch. Pathol. Lab. Med. 137, 462–466 (2013).
pubmed: 23544935
doi: 10.5858/arpa.2012-0078-RA
Welch, H. G. & Black, W. C. Using autopsy series to estimate the disease ‘reservoir’ for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127, 1023–1028 (1997).
pubmed: 9412284
doi: 10.7326/0003-4819-127-11-199712010-00014
Barreau, B., De Mascarel, I., Feuga, C., MacGrogan, G., Dilhuydy, M. H., Picot, V. et al. Mammography of ductal carcinoma in situ of the breast: Review of 909 cases with radiographic-pathologic correlations. Eur. J. Radiol. 54, 55–61 (2005).
pubmed: 15797293
doi: 10.1016/j.ejrad.2004.11.019
Holland, R., Hendriks, J. H., Vebeek, A. L., Mravunac, M. & Schuurmans Stekhoven, J. H. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 335, 519–522 (1990).
pubmed: 1968538
doi: 10.1016/0140-6736(90)90747-S
Thomas, J., Hanby, A., Pinder, S. E., Ball, G., Lawrence, G., Maxwell, A. et al. Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. Eur. J. Cancer 50, 1880–1890 (2014).
pubmed: 24874088
doi: 10.1016/j.ejca.2014.02.023
Pinder, S. E., Duggan, C., Ellis, I. O., Cuzick, J., Forbes, J. F., Bishop, H. et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br. J. Cancer 103, 94–100 (2010).
pubmed: 20517310
pmcid: 2905282
doi: 10.1038/sj.bjc.6605718
Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 80, 1798–1802 (1997).
Schnitt, S. J. & Collins, L. C. Biopsy Interpretation of the Breast (Lippincott Williams and Wilkins, Philadelphia, PA, 2013.
Thompson, A. M., Clements, K., Cheung, S., Pinder, S. E., Lawrence, G., Sawyer, E. et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project On behalf of the Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias) 1. Eur. J. Cancer 101, 210–219 (2018).
pubmed: 30092498
doi: 10.1016/j.ejca.2018.06.027
Elshof, L. E., Schaapveld, M., Schmidt, M. K., Rutgers, E. J., van Leeuwen, F. E. & Wesseling, J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res. Treat. 159, 553–563 (2016).
pubmed: 27624164
pmcid: 5021731
doi: 10.1007/s10549-016-3973-y
Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C. et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol. 19, 2263–2271 (2001).
pubmed: 11304780
doi: 10.1200/JCO.2001.19.8.2263
Worni, M., Akushevich, I., Greenup, R., Sarma, D., Ryser, M. D., Myers, E. R. et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J. Natl. Cancer Inst. 107, djv263 (2015).
pubmed: 26424776
pmcid: 4707192
doi: 10.1093/jnci/djv263
Morrow, M. & Katz, S. J. Addressing overtreatment in DCIS: what should physicians do now? J. Natl. Cancer Inst. 107, djv290 (2015).
pubmed: 26424780
doi: 10.1093/jnci/djv290
Fisher, E. R., Dignam, J., Tan-Chiu, E., Costantino, J., Fisher, B., Paik, S. et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86, 429–438 (1999).
pubmed: 10430251
doi: 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y
Elshof, L. E., Schmidt, M. K., Rutgers, E. J. T., van Leeuwen, F. E., Wesseling, J. & Schaapveld, M. Cause-specific mortality in a population-based cohort of 9799 women treated for ductal carcinoma in situ. Ann. Surg. 267, 952–958 (2017).
pmcid: 5916471
doi: 10.1097/SLA.0000000000002239
pubmed: 5916471
Fallowfield, L., Matthews, L., Francis, A., Jenkins, V. & Rea, D. Low grade ductal carcinoma in situ (DCIS): how best to describe it? Breast 23, 693–696 (2014).
pubmed: 24986765
doi: 10.1016/j.breast.2014.06.013
Ganz, P. A. Quality-of-life issues in patients with ductal carcinoma in situ. J. Natl. Cancer Inst. Monogr. 2010, 218–222 (2010).
pubmed: 20956834
pmcid: 5161073
doi: 10.1093/jncimonographs/lgq029
Hawley, S. T., Janz, N. K., Griffith, K. A., Jagsi, R., Friese, C. R., Kurian, A. W. et al. Recurrence risk perception and quality of life following treatment of breast cancer. Breast Cancer Res. Treat. 161, 557–565 (2017).
pubmed: 28004220
doi: 10.1007/s10549-016-4082-7
pmcid: 28004220
Ruddy, K. J., Meyer, M. E., Giobbie-Hurder, A., Emmons, K. M., Weeks, J. C., Winer, E. P. et al. Long-term risk perceptions of women with ductal carcinoma in situ. Oncologist 18, 362–368 (2013).
pubmed: 23568001
pmcid: 3639521
doi: 10.1634/theoncologist.2012-0376
Liu, Y., Pérez, M., Schootman, M., Aft, R. L., Gillanders, W. E., Ellis, M. J. et al. A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res. Treat. 124, 835–844 (2010).
pubmed: 20446031
pmcid: 3227389
doi: 10.1007/s10549-010-0912-1
van Gestel, Y. R. B. M., Voogd, A. C., Vingerhoets, A. J. J. M., Mols, F., Nieuwenhuijzen, G. A. P., van Driel, O. J. R. et al. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur. J. Cancer 43, 549–556 (2007).
pubmed: 17140788
doi: 10.1016/j.ejca.2006.10.010
pmcid: 17140788
Partridge, A., Adloff, K., Blood, E., Dees, E. C., Kaelin, C., Golshan, M. et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J. Natl. Cancer Inst. 100, 243–251 (2008).
pubmed: 18270338
doi: 10.1093/jnci/djn010
pmcid: 18270338
Davey, C., White, V., Warne, C., Kitchen, P., Villanueva, E. & Erbas, B. Understanding a ductal carcinoma in situ diagnosis: patient views and surgeon descriptions. Eur. J. Cancer Care 20, 776–784 (2011).
doi: 10.1111/j.1365-2354.2011.01265.x
Kim, C., Liang, L., Wright, F. C., Hong, N. J. L., Groot, G., Helyer, L. et al. Interventions are needed to support patient–provider decision-making for DCIS: a scoping review. Breast Cancer Res. Treat. 168, 1–14 (2017).
Sprague, B. L., Trentham-Dietz, A., Nichols, H. B., Hampton, J. M. & Newcomb, P. A. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res. Treat. 124, 487–495 (2010).
pubmed: 20361251
pmcid: 2924938
doi: 10.1007/s10549-010-0869-0
Lakhani, S. R., Audretsch, W., Cleton-Jensen, A. M., Cutuli, B., Ellis, I., Eusebi, V. et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur. J. Cancer 42, 2205–2211 (2006).
pubmed: 16876991
doi: 10.1016/j.ejca.2006.03.019
pmcid: 16876991
Ottesen, G. L., Graversen, H. P., Blichert-Toft, M., Christensen, I. J. & Andersen, J. A. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res. Treat. 62, 197–210 (2000).
pubmed: 11072784
doi: 10.1023/A:1006453915590
Janz, N. K., Li, Y., Zikmund-Fisher, B. J., Jagsi, R., Kurian, A. W., An, L. C. et al. The impact of doctor–patient communication on patients’ perceptions of their risk of breast cancer recurrence. Breast Cancer Res. Treat. 161, 525–535 (2017).
pubmed: 27943007
doi: 10.1007/s10549-016-4076-5
pmcid: 27943007
Lee, K. L., Janz, N. K., Zikmund-Fisher, B. J., Jagsi, R., Wallner, L. P., Kurian, A. W. et al. What factors influence women’s perceptions of their systemic recurrence risk after breast cancer treatment? Med. Decis. Making 38, 95–106 (2018).
pubmed: 28814131
doi: 10.1177/0272989X17724441
pmcid: 28814131
Martínez-Pérez, C., Turnbull, A. K., Ekatah, G. E., Arthur, L. M., Sims, A. H., Thomas, J. S. et al. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. Cancer Treat. Rev. 55, 163–172 (2017).
pubmed: 28402908
doi: 10.1016/j.ctrv.2017.03.009
pmcid: 28402908
Bijker, N., Donker, M., Wesseling, J., den Heeten, G. J., Rutgers, E. J. Is DCIS breast cancer, and how do I treat it? Curr. Treat. Options Oncol. 14, 75–87 (2013).
pubmed: 23239193
doi: 10.1007/s11864-012-0217-1
pmcid: 23239193
Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J. Natl. Cancer Inst. 103, 478–488 (2011).
pubmed: 21398619
pmcid: 3107729
doi: 10.1093/jnci/djr027
Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C. et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. Monogr. 2010, 162–177 (2010).
pubmed: 20956824
doi: 10.1093/jncimonographs/lgq039
pmcid: 20956824
Corradini, S., Pazos, M., Schönecker, S., Reitz, D., Niyazi, M., Ganswindt, U. et al. Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. Radiat. Oncol. 13, 1–9 (2018).
doi: 10.1186/s13014-018-0964-7
van Roozendaal, L. M., Goorts, B., Klinkert, M., Keymeulen, K. B. M. I., De Vries, B., Strobbe, L. J. A. et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res. Treat. 156, 517–525 (2016).
pubmed: 27083179
pmcid: 4837213
doi: 10.1007/s10549-016-3783-2
Ansari, B., Ogston, S. A., Purdie, C. A., Adamson, D. J., Brown, D. C. & Thompson, A. M. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br. J. Surg. 95, 547–554 (2008).
pubmed: 18386775
doi: 10.1002/bjs.6162
pmcid: 18386775
Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V. & Sun, P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 1, 888–896 (2015).
pubmed: 26291673
doi: 10.1001/jamaoncol.2015.2510
pmcid: 26291673
Yarnold, J. Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence Guideline 2009. Clin. Oncol. 21, 159–160 (2009).
doi: 10.1016/j.clon.2008.12.008
Cuzick, J., Sestak, I., Pinder, S. E., Ellis, I. O., Forsyth, S., Bundred, N. J. et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 12, 21–29 (2011).
pubmed: 21145284
doi: 10.1016/S1470-2045(10)70266-7
Staley, H., McCallum, I. & Bruce, J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast 23, 546–551 (2014).
Maxwell, A. J., Clements, K., Hilton, B., Dodwell, D. J., Evans, A., Kearins, O., et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur. J. Surg. Oncol. 44, 429–435 (2018).
pubmed: 29398324
doi: 10.1016/j.ejso.2017.12.007
Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C. et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387, 866–873 (2016).
pubmed: 26686313
pmcid: 4769326
doi: 10.1016/S0140-6736(15)01129-0
Ward, E. M., DeSantis, C. E., Lin, C. C., Kramer, J. L., Jemal, A., Kohler, B. et al. Cancer statistics: breast cancer in situ. CA Cancer J. Clin. 65, 481–495 (2015).
pubmed: 26431342
doi: 10.3322/caac.21321
Francis, A., Thomas, J., Fallowfield, L., Wallis, M., Bartlett, J. M., Brookes, C. et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur. J. Cancer 51, 2296–2303 (2015).
pubmed: 26296293
doi: 10.1016/j.ejca.2015.07.017
Comparison of operative versus medical endocrine therapy for low risk DCIS: the COMET Trial. http://www.pcori.org/research-results/2016/comparison-operative-versus-medical-endocrine-therapy-low-risk-dcis-comet .
Hwang, E. S., Hyslop, T., Lynch, T., Frank, E., Pinto, D., Basila, D. et al. The COMET (Comparison of Operative to Monitoring and Endocrine Therapy) Trial: a phase III randomized trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9, e026797 (2019).
pubmed: 30862637
pmcid: 6429899
doi: 10.1136/bmjopen-2018-026797
Elshof, L. E., Tryfonidis, K., Slaets, L., van Leeuwen-Stok, A. E., Skinner, V. P., Dif, N. et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur. J. Cancer 51, 1497–1510 (2015).
pubmed: 26025767
doi: 10.1016/j.ejca.2015.05.008
Brennan, M. E., Turner, R. M., Ciatto, S., Marinovich, M. L., French, J. R., Macaskill, P. et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260, 119–128 (2011).
pubmed: 21493791
doi: 10.1148/radiol.11102368
Grimm, L. J., Ryser, M. D., Partridge, A. H., Thompson, A. M., Thomas, J. S., Wesseling, J., et al. Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. Ann. Surg. Oncol. 24, 3534–3540 (2017).
pubmed: 28795370
pmcid: 6414216
doi: 10.1245/s10434-017-6018-9
Sontag, L. & Axelrod, D. E. Evaluation of pathways for progression of heterogeneous breast tumors. J. Theor. Biol. 232, 179–189 (2005).
pubmed: 15530488
doi: 10.1016/j.jtbi.2004.08.002
Casasent, A. K., Schalck, A., Gao, R., Sei, E., Long, A., Pangburn, W., et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell 172, 205.e12–217.e12 (2018).
pubmed: 29307488
pmcid: 5766405
doi: 10.1016/j.cell.2017.12.007
Casasent, A. K., Edgerton, M. & Navin, N. E. Genome evolution in ductal carcinoma in situ: invasion of the clones. J. Pathol. 241, 208–218 (2017).
pubmed: 27861897
doi: 10.1002/path.4840
Narod, S. A. & Sopik, V. Is invasion a necessary step for metastases in breast cancer? Breast Cancer Res. Treat. 169, 9–23 (2018).
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751–759 (2015).
pubmed: 26099045
pmcid: 4500826
doi: 10.1038/nm.3886
Ashworth, A., Lord, C. J. & Reis-Filho, J. S. Erratum: Genetic interactions in cancer progression and treatment. Cell 145, 30–38 (2011).
pubmed: 21458666
doi: 10.1016/j.cell.2011.03.020
Cowell, C. F., Weigelt, B., Sakr, R. A., Ng, C. K. Y., Hicks, J., King, T. A. et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol. Oncol. 7, 859–869 (2013).
pubmed: 23890733
pmcid: 5528459
doi: 10.1016/j.molonc.2013.07.005
Hernandez, L., Wilkerson, P. M., Lambros, M. B., Campion-Flora, A., Rodrigues, D. N., Gauthier, A. et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J. Pathol. 227, 42–52 (2012).
pubmed: 22252965
pmcid: 4975517
doi: 10.1002/path.3990
Kim, S. Y., Jung, S.-H., Kim, M. S., Baek, I.-P., Lee, S. H., Kim, T.-M. et al. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget 6, 7597–7607 (2015).
pubmed: 25831047
pmcid: 4480702
Abba, M. C., Gong, T., Lu, Y., Lee, J., Zhong, Y., Lacunza, E. et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res. 75, 3980–3990 (2015).
pubmed: 26249178
pmcid: 4768486
doi: 10.1158/0008-5472.CAN-15-0506
Pang, J.-M. B., Savas, P., Fellowes, A. P., Mir Arnau, G., Kader, T., Vedururu, R. et al. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Mod. Pathol. 30, 952–963 (2017).
pubmed: 28338653
doi: 10.1038/modpathol.2017.21
Heselmeyer-Haddad, K., Berroa Garcia, L. Y., Bradley, A., Ortiz-Melendez, C., Lee, W. J., Christensen, R. et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am. J. Pathol. 181, 1807–1822 (2012).
pubmed: 23062488
pmcid: 3483801
doi: 10.1016/j.ajpath.2012.07.012
Lesurf, R., Aure, M. R. R., Mork, H. H., Vitelli, V., Oslo Breast Cancer Research, C., Lundgren, S. et al. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. Cell Rep. 16, 1166–1179 (2016).
pubmed: 27396337
doi: 10.1016/j.celrep.2016.06.051
pmcid: 27396337
Miron, A., Varadi, M., Carrasco, D., Li, H., Luongo, L., Kim, H. J. et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 70, 5674–5678 (2010).
pubmed: 20551053
pmcid: 2905503
doi: 10.1158/0008-5472.CAN-08-2660
Pape-Zambito, D., Jiang, Z., Wu, H., Devarajan, K., Slater, C. M., Cai, K. Q. et al. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients. PLoS ONE 9, e100488 (2014).
pubmed: 24978026
pmcid: 4076240
doi: 10.1371/journal.pone.0100488
Sinha, V. C. & Piwnica-Worms, H. Intratumoral heterogeneity in ductal carcinoma in situ: chaos and consequence. J. Mammary Gland Biol. Neoplasia 23, 191–205 (2018).
Carraro, D. M., Elias, E. V. & Andrade, V. P. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression. Biosci. Rep. 34, e00090 (2014).
pubmed: 27919043
pmcid: 3894794
doi: 10.1042/BSR20130077
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726 (2013).
pubmed: 23415222
pmcid: 3575604
doi: 10.1016/j.cell.2013.01.019
Morris, L. G., Riaz, N., Desrichard, A., Senbabaoglu, Y., Hakimi, A. A., Makarov, V. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051–10063 (2016).
pubmed: 26840267
pmcid: 4891103
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
pubmed: 19204204
pmcid: 2667820
doi: 10.1200/JCO.2008.18.1370
Gil Del Alcazar, C. R., Huh, S. J., Ekram, M. B., Trinh, A., Liu, L. L., Beca, F. et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 7, 1098–1115 (2017).
pubmed: 28652380
pmcid: 5628128
doi: 10.1158/2159-8290.CD-17-0222
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228–241 (2016).
pubmed: 26667975
doi: 10.1038/nrclinonc.2015.215
pmcid: 26667975
Latta, E. K., Tjan, S., Parkes, R. K. & O’Malley, F. P. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 15, 1318–1325 (2002).
pubmed: 12481013
doi: 10.1097/01.MP.0000038462.62634.B1
pmcid: 12481013
Purdie, C. A., Baker, L., Ashfield, A., Chatterjee, S., Jordan, L. B., Quinlan, P. et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br. J. Cancer 103, 475–481 (2010).
pubmed: 20664587
pmcid: 2939790
doi: 10.1038/sj.bjc.6605799
Gorringe, K. L., Hunter, S. M., Pang, J.-M., Opeskin, K., Hill, P., Rowley, S. M. et al. Copy number analysis of ductal carcinoma in situ with and without recurrence. Mod. Pathol. 28, 1174–1184 (2015).
pubmed: 26321097
doi: 10.1038/modpathol.2015.75
pmcid: 26321097
Borgquist, S., Zhou, W., Jirström, K., Amini, R.-M., Sollie, T., Sørlie, T. et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer 15, 468 (2015).
pubmed: 26062614
pmcid: 4464713
doi: 10.1186/s12885-015-1479-3
Bremer, T., Whitworth, P. W., Patel, R., Savala, J., Barry, T., Lyle, S., et al. A biological signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin. Cancer Res. 24, 5895–5901 (2018).
Rakovitch, E., Nofech-Mozes, S., Hanna, W., Sutradhar, R., Baehner, F. L., Miller, D. P. et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J. Natl. Cancer Inst. 109, 1–8 (2017).
doi: 10.1093/jnci/djw256
Gierisch, J. M., Myers, E. R., Schmit, K. M., Crowley, M. J., McCrory, D. C., Chatterjee, R. et al. Prioritization of research addressing management strategies for ductal carcinoma in situ. Ann. Intern. Med. 160, 484–491 (2014).
pubmed: 24567146
doi: 10.7326/M13-2548
Cancer Research UK. Grand Challenges. https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award .
Bluman, L. G., Borstelmann, N. A., Rimer, B. K., Iglehart, J. D. & Winer, E. P. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J. Womens Heal Gend. Based Med. 10, 589–598 (2001).
doi: 10.1089/15246090152543175
Partridge, A. H., Elmore, J. G., Saslow, D., Mccaskill-stevens, W. & Schnitt, S. J. Challenges in ductal carcinoma in situ risk communication and decision-making report from an American Cancer Society and National Cancer Institute Workshop. CA Cancer J. Clin. 62, 203–210 (2012).
pubmed: 22488610
pmcid: 4112288
doi: 10.3322/caac.21140